{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:46:38Z","timestamp":1770885998462,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:00:00Z","timestamp":1509062400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40261-017-0582-4","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T07:57:15Z","timestamp":1509091035000},"page":"39-48","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction"],"prefix":"10.1007","volume":"38","author":[{"given":"Mikie","family":"Yamato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Oita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsutaka","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"issue":"3","key":"582_CR1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0735-1097(97)00220-9","volume":"30","author":"VR Vorperian","year":"1997","unstructured":"Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"582_CR2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00380-014-0487-6","volume":"30","author":"F Benassi","year":"2015","unstructured":"Benassi F, Molardi A, Righi E, Santangelo R, Meli M. ECMO for pulmonary rescue in an adult with amiodarone-induced toxicity. Heart Vessels. 2015;30(3):410\u20135.","journal-title":"Heart Vessels"},{"issue":"12","key":"582_CR3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/qjmed\/hcg158","volume":"96","author":"J Sidhu","year":"2003","unstructured":"Sidhu J, Jenkins D. Men are at increased risk of amiodarone-associated thyrotoxicosis in the UK. QJM. 2003;96(12):949\u201350.","journal-title":"QJM"},{"issue":"6","key":"582_CR4","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1590\/S0004-27302005000600010","volume":"49","author":"BD Schaan","year":"2005","unstructured":"Schaan BD, Cunha CP, Francisconi A, Zottis B, Brum G, Bruch RS, et al. Amiodarone-induced thyroid dysfunction in a tertiary center in south Brazil. Arq Bras Endocrinol Metab. 2005;49(6):916\u201322.","journal-title":"Arq Bras Endocrinol Metab"},{"issue":"6","key":"582_CR5","first-page":"434","volume":"16","author":"KF Lee","year":"2010","unstructured":"Lee KF, Lee KM, Fung TT. Amiodarone-induced thyroid dysfunction in the Hong Kong Chinese population. Hong Kong Med J. 2010;16(6):434\u20139.","journal-title":"Hong Kong Med J"},{"issue":"3","key":"582_CR6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2265.2011.04087.x","volume":"75","author":"S Ahmed","year":"2011","unstructured":"Ahmed S, Van Gelder IC, Wiesfeld AC, Van Veldhuisen DJ, Links TP. Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf). 2011;75(3):388\u201394.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"582_CR7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ijcard.2012.02.015","volume":"167","author":"MN Stan","year":"2013","unstructured":"Stan MN, Ammash NM, Warnes CA, Brennan MD, Thapa P, Nannenga MR, et al. Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease\u2014a cohort study. Int J Cardiol. 2013;167(3):821\u20136.","journal-title":"Int J Cardiol"},{"issue":"1","key":"582_CR8","first-page":"2","volume":"63","author":"I Zosin","year":"2012","unstructured":"Zosin I, Balas M. Amiodarone-induced thyroid dysfunction in an iodine-replete area: epidemiological and clinical data. Endokrynol Polska. 2012;63(1):2\u20139.","journal-title":"Endokrynol Polska"},{"issue":"2","key":"582_CR9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2265.1987.tb00781.x","volume":"26","author":"E Martino","year":"1987","unstructured":"Martino E, Aghini-Lombardi F, Mariotti S, Bartalena L, Lenziardi M, Ceccarelli C, et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. Clin Endocrinol (Oxf). 1987;26(2):227\u201337.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"582_CR10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0002-9343(91)90187-3","volume":"91","author":"MD Trip","year":"1991","unstructured":"Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991;91(5):507\u201311.","journal-title":"Am J Med"},{"issue":"11\u201312","key":"582_CR11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2298\/MPNS1112533A","volume":"64","author":"Z Aleksic","year":"2011","unstructured":"Aleksic Z, Aleksic A. Incidence of amiodarone-induced thyroid dysfunction and predictive factors for their occurrence. Med Pregl. 2011;64(11\u201312):533\u20138.","journal-title":"Med Pregl"},{"issue":"23","key":"582_CR12","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1001\/archinte.1994.00420230115013","volume":"154","author":"E Martino","year":"1994","unstructured":"Martino E, Aghini-Lombardi F, Bartalena L, Grasso L, Loviselli A, Velluzzi F, et al. Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid autoimmune disease. Arch Intern Med. 1994;154(23):2722\u20136.","journal-title":"Arch Intern Med"},{"issue":"1","key":"582_CR13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7326\/0003-4819-101-1-28","volume":"101","author":"E Martino","year":"1984","unstructured":"Martino E, Safran M, Aghini-Lombardi F, Rajatanavin R, Lenziardi M, Fay M, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med. 1984;101(1):28\u201334.","journal-title":"Ann Intern Med"},{"issue":"1\u20134","key":"582_CR14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000180696","volume":"26","author":"E Martino","year":"1987","unstructured":"Martino E, Aghini-Lombardi F, Mariotti S, Bartalena L, Braverman L, Pinchera A. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res. 1987;26(1\u20134):158\u201371.","journal-title":"Horm Res"},{"key":"582_CR15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-6614-4-14","volume":"4","author":"TT Zava","year":"2011","unstructured":"Zava TT, Zava DT. Assessment of Japanese iodine intake based on seaweed consumption in Japan: a literature-based analysis. Thyroid Res. 2011;4:14.","journal-title":"Thyroid Res"},{"issue":"2","key":"582_CR16","first-page":"240","volume":"22","author":"E Martino","year":"2001","unstructured":"Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22(2):240\u201354.","journal-title":"Endocr Rev"},{"issue":"6","key":"582_CR17","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0090-9556(25)08220-0","volume":"21","author":"G Fabre","year":"1993","unstructured":"Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos. 1993;21(6):978\u201385.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"582_CR18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1742-7843.2010.00669.x","volume":"108","author":"N Hanioka","year":"2011","unstructured":"Hanioka N, Matsumoto K, Saito Y, Narimatsu S. Influence of CYP2C8*13 and CYP2C8*14 alleles on amiodarone N-deethylation. Basic Clin Pharmacol Toxicol. 2011;108(5):359\u201362.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"582_CR19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bcp.2010.11.002","volume":"81","author":"A Zahno","year":"2011","unstructured":"Zahno A, Brecht K, Morand R, Maseneni S, Torok M, Lindinger PW, et al. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol. 2011;81(3):432\u201341.","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"582_CR20","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0090-9556(24)15077-5","volume":"28","author":"K Ohyama","year":"2000","unstructured":"Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000;28(11):1303\u201310.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"582_CR21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1067\/mcp.2000.107047","volume":"67","author":"PT Pollak","year":"2000","unstructured":"Pollak PT, Bouillon T, Shafer SL. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther. 2000;67(6):642\u201352.","journal-title":"Clin Pharmacol Ther"},{"issue":"24","key":"582_CR22","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1016\/0006-2952(89)90648-5","volume":"38","author":"SA Beddows","year":"1989","unstructured":"Beddows SA, Page SR, Taylor AH, McNerney R, Whitley GS, Johnstone AP, et al. Cytotoxic effects of amiodarone and desethylamiodarone on human thyrocytes. Biochem Pharmacol. 1989;38(24):4397\u2013403.","journal-title":"Biochem Pharmacol"},{"issue":"4 Pt 2","key":"582_CR23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0002-8703(83)90006-6","volume":"106","author":"DW Holt","year":"1983","unstructured":"Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J. 1983;106(4 Pt 2):840\u20137.","journal-title":"Am Heart J"},{"issue":"3","key":"582_CR24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00228-017-2195-5","volume":"73","author":"M Yamato","year":"2017","unstructured":"Yamato M, Wada K, Fujimoto M, Hosomi K, Hayashi T, Oita A, et al. Association between N-desethylamiodarone\/amiodarone ratio and amiodarone-induced thyroid dysfunction. Eur J Clin Pharmacol. 2017;73(3):289\u201396.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"582_CR25","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.amjmed.2004.11.028","volume":"118","author":"S Basaria","year":"2005","unstructured":"Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005;118(7):706\u201314.","journal-title":"Am J Med"},{"issue":"10","key":"582_CR26","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1248\/bpb.28.1934","volume":"28","author":"A Kashima","year":"2005","unstructured":"Kashima A, Funahashi M, Fukumoto K, Komamura K, Kamakura S, Kitakaze M, et al. Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population. Biol Pharm Bull. 2005;28(10):1934\u20138.","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"582_CR27","first-page":"420","volume":"69","author":"E Berta","year":"2014","unstructured":"Berta E, Harangi M, Zsiros N, Nagy EV, Paragh G, Bodor M. Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients. Pharmazie. 2014;69(6):420\u20133.","journal-title":"Pharmazie"},{"issue":"4","key":"582_CR28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/156800805774912971","volume":"5","author":"NJ Sarlis","year":"2005","unstructured":"Sarlis NJ, Gourgiotis L. Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics. Curr Drug Targets Immune Endocr Metab Disord. 2005;5(4):439\u201348.","journal-title":"Curr Drug Targets Immune Endocr Metab Disord"},{"issue":"4","key":"582_CR29","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bbrc.2010.02.058","volume":"393","author":"MA Istrate","year":"2010","unstructured":"Istrate MA, Nussler AK, Eichelbaum M, Burk O. Regulation of CYP3A4 by pregnane X receptor: the role of nuclear receptors competing for response element binding. Biochem Biophys Res Commun. 2010;393(4):688\u201393.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"582_CR30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.taap.2012.03.017","volume":"263","author":"YJ Park","year":"2012","unstructured":"Park YJ, Lee EK, Lee YK, Park DJ, Jang HC, Moore DD. Opposing regulation of cytochrome P450 expression by CAR and PXR in hypothyroid mice. Toxicol Appl Pharmacol. 2012;263(2):131\u20137.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"582_CR31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1507\/endocrj.46.443","volume":"46","author":"K Sato","year":"1999","unstructured":"Sato K, Miyakawa M, Eto M, Inaba T, Matsuda N, Shiga T, et al. Clinical characteristics of amiodarone-induced thyrotoxicosis and hypothyroidism in Japan. Endocr J. 1999;46(3):443\u201351.","journal-title":"Endocr J"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0582-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0582-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0582-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:27:34Z","timestamp":1750966054000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0582-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0582-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,27]]}}}